Changming Xia, PhD

Director
Regeneron Pharmaceuticals Inc.
Tarrytown, New York, United States

Presentation(s):

• Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improves Outcomes Compared with Placebo Plus High-Dose Inhaled Corticosteroid in Pediatric Patients with Uncontrolled Asthma

  Monday, April 28, 2025
  9:15am – 9:30am HST

  Disclosure(s): Regeneron Pharmaceuticals Inc. (Ongoing) (Products/Services: Employment with an ineligible company); Regeneron Pharmaceuticals Inc. − employees and shareholders (Ongoing) (Products/Services: Employment with an ineligible company, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds)